Vincent Fradet, Ph.D. - Publications

Affiliations: 
2012 Biomedical Sciences Université de Montréal, Montréal, Canada 
Area:
Oncology, Public Health, Microbiology Biology

82/120 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Lachance G, Robitaille K, Laaraj J, Gevariya N, Varin TV, Feldiorean A, Gaignier F, Julien IB, Xu HW, Hallal T, Pelletier JF, Bouslama S, Boufaied N, Derome N, Bergeron A, ... ... Fradet V, et al. The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. Nature Communications. 15: 3431. PMID 38654015 DOI: 10.1038/s41467-024-45332-w  0.421
2024 Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Lodde M, Racine É, ... ... Fradet V, et al. A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. Communications Medicine. 4: 56. PMID 38519581 DOI: 10.1038/s43856-024-00456-4  0.453
2023 Savard J, Moussa H, Pelletier JF, Julien P, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Pouliot F, Lodde M, Fradet Y, Robitaille K, Fradet V. Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial. Cancer Medicine. 12: 20163-20176. PMID 37787025 DOI: 10.1002/cam4.6598  0.338
2023 Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, Siemens DR, Shayegan B, Klotz L, Luke PP, Niazi T, Lavallee LT, Mousavi N, Hamilton RJ, Chin JL, et al. The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis. Jacc. Cardiooncology. 5: 70-81. PMID 36875906 DOI: 10.1016/j.jaccao.2022.09.008  0.479
2022 Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and Translational Medicine. 12: e581. PMID 35075795 DOI: 10.1002/ctm2.581  0.343
2022 Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens R, Niazi T, Fradet V, Foster W, Duceppe E, Taussky D, Hamilton R, Lavallee L, Brown I, Chin J, Gopaul D, et al. Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy. The Journal of Urology. 101097JU000000000000. PMID 34978211 DOI: 10.1097/JU.0000000000002384  0.465
2021 Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition. 5: nzab106. PMID 34870071 DOI: 10.1093/cdn/nzab106  0.509
2021 Lamarre M, Tremblay T, Bansept MA, Robitaille K, Fradet V, Giguère D, Boudreau D. A glycan-based plasmonic sensor for prostate cancer diagnosis. The Analyst. PMID 34623365 DOI: 10.1039/d1an00789k  0.44
2020 Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research : McR. PMID 33262291 DOI: 10.1158/1541-7786.MCR-20-0316  0.391
2020 Fervaha G, Izard JP, Tripp DA, Aghel N, Shayegan B, Klotz L, Niazi T, Fradet V, Taussky D, Lavallée LT, Hamilton RJ, Brown I, Chin J, Gopaul D, Violette PD, et al. Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 33212008 DOI: 10.5489/cuaj.6912  0.465
2020 Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A. Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 32569568 DOI: 10.5489/Cuaj.6388  0.54
2020 Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of Urology. 101097JU000000000000. PMID 31899651 DOI: 10.1097/Ju.0000000000000714  0.571
2020 Pinthus JH, Shayegan B, Klotz L, Siemens DR, Luke PP, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton RJ, Brown I, Chin J, Gopaul D, et al. The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. Journal of Clinical Oncology. 38: 364-364. DOI: 10.1200/Jco.2020.38.6_Suppl.364  0.523
2020 Pavlovich* CP, Hyndman ME, Eure G, Ghai S, Fradet V. MP75-09 MICRO-ULTRASOUND IMAGING OF MEN WITH FAMILY HISTORY OF PROSTATE CANCER The Journal of Urology. 203: e1144-e1145. DOI: 10.1097/Ju.0000000000000961.09  0.511
2020 Pinthus* J, Shayegan B, Siemens R, Klotz L, Luke P, Niazi T, Fradet V, Fradet Y, Duceppe E, Lavallee L, Mousavi N, Hamilton R, Brown I, Chin J, Gopaul D, et al. PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION The Journal of Urology. 203: e270. DOI: 10.1097/Ju.0000000000000847.010  0.503
2019 McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P. Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical Genitourinary Cancer. PMID 31594737 DOI: 10.1016/J.Clgc.2019.07.016  0.309
2019 Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European Urology Oncology. PMID 31411963 DOI: 10.1016/J.Euo.2019.01.009  0.498
2019 Moussa H, Nguile-Makao M, Robitaille K, Guertin MH, Allaire J, Pelletier JF, Moreel X, Gevariya N, Diorio C, Desmeules P, Têtu B, Lamarche B, Julien P, Fradet V. Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. Nutrients. 11. PMID 31315273 DOI: 10.3390/Nu11071616  0.532
2019 Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M. Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic Oncology. PMID 30871997 DOI: 10.1016/J.Urolonc.2019.01.017  0.313
2019 Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Delouya G, Taussky D, Lavallee L, Johnson C, et al. PD30-03 PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH A NEW DIAGNOSIS OF PROSTATE CANCER: RATES AND PREDICTORS OF DEPRESSIVE SYMPTOMS IN THE RADICAL PC STUDY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556135.36362.37  0.436
2019 Pavlovich* C, Hyndman ME, Eure G, Ghai S, Fradet V. PD23-04 A MULTI-INSTITUTIONAL RANDOMIZED CONTROLLED TRIAL COMPARING NOVEL FIRST GENERATION HIGH-RESOLUTION MICRO-ULTRASOUND WITH CONVENTIONAL FREQUENCY ULTRASOUND FOR TRANSRECTAL PROSTATE BIOPSY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555772.65881.Fd  0.341
2019 Fervaha* G, Izard J, Tripp D, Rajan S, Karampatos S, Shayegan B, Matsumoto E, Niazi T, Chen-Tournoux A, Fradet V, Fradet Y, Duceppe E, Lavallee L, Johnson C, Chin J, et al. MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555600.69863.72  0.545
2019 Pavlovich C, Hyndman M, Eure G, Ghai S, Fradet V. A multi-institutional randomized controlled trial comparing novel first generation high-resolution micro-ultrasound with conventional frequency ultrasound for transrectal prostate biopsy European Urology Supplements. 18: e737. DOI: 10.1016/s1569-9056(19)30540-8  0.326
2018 Gevariya N, Besançon M, Robitaille K, Picard V, Diabaté L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V. Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. The Prostate. PMID 30073695 DOI: 10.1002/Pros.23706  0.507
2018 Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F. Increased Prostate Cancer Glucose Metabolism Detected byF-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus. PMID 29609897 DOI: 10.1016/J.Euf.2018.03.008  0.494
2018 Guertin MH, Robitaille K, Pelletier JF, Duchesne T, Julien P, Savard J, Bairati I, Fradet V. Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. Bmc Cancer. 18: 64. PMID 29321047 DOI: 10.1186/S12885-017-3979-9  0.549
2018 Gotto G, Fradet V, Drachenberg D, Sabbagh R, Rendon RA, Shayegan B, Danielson BL, Casey R, Chan K, Camacho F, Zardan A, Hew H, Feifer A. Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P). Journal of Clinical Oncology. 36: 196-196. DOI: 10.1200/Jco.2018.36.6_Suppl.196  0.427
2018 Lavallee E, Bergeron M, Buteau F, Duchesnay N, Blouin A, Fradet Y, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Beauregard J, Pouliot F. Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration European Urology Supplements. 17: e1510. DOI: 10.1016/S1569-9056(18)31890-6  0.531
2018 Lachance G, Geveriya N, Robitaille K, Bergeron A, Picard V, Leclerc M, Joly C, Fradet Y, Droit A, Marette A, Fradet V. MP70-17 DECIPHERING THE EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2261  0.526
2018 Beaudoin L, Gevariya N, Robitaille K, Guertin M, Pelletier J, Julien P, Fradet V. PD42-09 EFFECTS OF OMEGA-3-RICH FISH OIL (MAG-EPA) ON PROSTATE CANCER: PRELIMINARY RESULTS OF A CLINICAL TRIAL Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1962  0.438
2018 Hyndman ME, Pavlovich CP, Eure G, Fradet V, Ghai S. PD37-06 PROSPECTIVE VALIDATION OF PRI-MUS™, THE PROSTATE RISK IDENTIFICATION USING MICRO-ULTRASOUND PROTOCOL FOR REAL-TIME DETECTION OF PROSTATE CANCER USING HIGH-RESOLUTION MICRO-ULTRASOUND IMAGING Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1741  0.519
2017 Vigneault É, Savard J, Savard MH, Ivers H, Després P, Foster W, Martin AG, Fradet V. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29106365 DOI: 10.5489/Cuaj.4428  0.562
2017 Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y. Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5α-reductase inhibitors. Bju International. PMID 28972698 DOI: 10.1111/Bju.14041  0.545
2017 Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus. PMID 28753860 DOI: 10.1016/J.Euf.2017.02.007  0.428
2017 Vigneault É, Savard J, Savard M, Ivers H, Després P, Foster W, Martin A, Fradet V. Supplementary data: Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French- Canadian population Canadian Urological Association Journal. 11: E461-4. DOI: 10.5489/Cuaj.5101  0.51
2017 Morin F, Beauregard J, Bergeron M, Nguilé-Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. Journal of Clinical Oncology. 35: e590-e590. DOI: 10.1200/Jco.2017.35.6_Suppl.E590  0.392
2017 Feifer A, Fradet V, Drachenberg D, Gotto G, Rendon RA, Sabbagh R, Shayegan B, Danielson BL, Casey R, Zardan A, Camacho F, Hew H. Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). Journal of Clinical Oncology. 35: 238-238. DOI: 10.1200/Jco.2017.35.6_Suppl.238  0.337
2017 Pinthus J, Klotz L, Lukka H, Devereaux PJ, Pohl K, Roifman I, Fradet V, Siemens R, Wallington T, Bobby S, Matsumoto E, Corbett T, Duivenvoorden W, Dehghan M, Mourtzakis M, et al. MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.468  0.562
2016 Vigneault E, Savard J, Ivers H, Savard MH, Fradet V, Després P, Foster W, Martin AG. Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC). International Journal of Radiation Oncology, Biology, Physics. 96: E531-E532. PMID 27674940 DOI: 10.1016/J.Ijrobp.2016.06.1960  0.553
2016 Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, Pavlovich CP. Assessing Cancer Risk in Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Protocol of Prostate Risk Identification Using Micro-Ultrasound. The Journal of Urology. PMID 26791931 DOI: 10.1016/J.Juro.2015.12.093  0.533
2016 Pinthus JH, Klotz L, Lukka H, Duivenvoorden WC, Pettit S, Pohl K, Siemens DR, Fradet V, Mourtzakis M, Kavsac P, Devereaux P, Leong D. The RADICAL-PC trial. Journal of Clinical Oncology. 34: 178-178. DOI: 10.1200/Jco.2016.34.2_Suppl.178  0.477
2016 Wodlinger B, Ghai S, Eure G, Fradet V, Hyndman E, Mcgrath T, Pavlovich C. Micro-ultrasound of the prostate, PRI-MUS™ protocol guidance along with clinical variables: Combined approach for reducing unnecessary biopsies European Urology Supplements. 15: e1513-e1514. DOI: 10.1016/S1569-9056(16)30358-X  0.457
2016 Wodlinger B, Ghai S, Eure G, Fradet V, Hyndman E, Mcgrath T, Pavlovich C. Using patient screening data and machine learning algorithms to improve PRI-MUS™ accuracy with micro-ultrasound-based prostate biopsies European Urology Supplements. 15: e1499-e1500. DOI: 10.1016/S1569-9056(16)30350-5  0.391
2016 Vigneault E, Savard J, Ivers H, Savard M, Fradet V, Després P, Foster W, Martin A. 141: Validation of a French Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC) Radiotherapy and Oncology. 120: S52-S53. DOI: 10.1016/S0167-8140(16)33540-X  0.553
2015 Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 9: 307-14. PMID 26664661 DOI: 10.5489/Cuaj.2707  0.584
2015 Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, Fradet V, Turgeon AF. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. Jama Oncology. 1: 1261-9. PMID 26378418 DOI: 10.1016/J.Ijrobp.2013.06.404  0.542
2015 Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagnostic Pathology. 10: 67. PMID 26070608 DOI: 10.1186/S13000-015-0294-0  0.492
2015 Allaire J, Moreel X, Labonté MÈ, Léger C, Caron A, Julien P, Lamarche B, Fradet V. Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. European Journal of Clinical Nutrition. PMID 25758837 DOI: 10.1038/Ejcn.2015.7  0.443
2015 Perrault L, Fradet V, Lauzon V, Lelorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis Journal of the Canadian Urological Association. 9: 307-314. DOI: 10.5489/cuaj.2707  0.623
2015 Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. 322 Development and validation of a post-DRE urine-based multigene signature for detection of aggressive prostate cancer prior to biopsy European Urology Supplements. 14: e322. DOI: 10.1016/S1569-9056(15)60319-0  0.551
2015 Haince J, Beaudry G, Paquet E, Aaron L, Sabbagh R, Fradet V, Fleshner N, Fradet Y. MP1-03 VALIDATED URINE-BASED MULTIGENE SIGNATURE FOR DETECTION OF AGGRESSIVE PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.166  0.557
2014 Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V. IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Research and Reports in Urology. 6: 27-34. PMID 24892030 DOI: 10.2147/Rru.S58643  0.477
2014 Moreel X, Allaire J, Léger C, Caron A, Labonté MÈ, Lamarche B, Julien P, Desmeules P, Têtu B, Fradet V. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prevention Research (Philadelphia, Pa.). 7: 766-76. PMID 24824038 DOI: 10.1158/1940-6207.Capr-13-0349  0.499
2014 Ben-Zvi T, Desmeules P, Hovington H, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V. MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2514  0.51
2013 Mauermann J, Fradet V, Fradet Y. Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that is the question. European Urology. 64: 28-9. PMID 23159455 DOI: 10.1016/J.Eururo.2012.10.047  0.4
2013 Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. European Urology. 64: 19-25. PMID 22901983 DOI: 10.1016/J.Eururo.2012.08.002  0.301
2013 Bouchard F, Rimac G, Blouin A, Lefebvre V, Têtu B, Hovington H, Lemay C, Fradet V, Lacombe L, Fradet Y, Dujardin T, Tiguert R, Pouliot F. 2199 GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2108  0.325
2013 Blouin A, Rimac G, Bouchard F, Lemay C, Fradet V, Caron A, Fradet Y, Lacombe L, Dujardin T, Tigert R, Beauregard J, Pouliot F. 241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1621  0.44
2012 Trudel D, Labbé DP, Bairati I, Fradet V, Bazinet L, Têtu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecologic Oncology. 126: 491-8. PMID 22564714 DOI: 10.1016/J.Ygyno.2012.04.048  0.342
2012 Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. European Urology. 62: 88-96. PMID 22209174 DOI: 10.1016/J.Eururo.2011.12.021  0.502
2012 Otzetov A, Fradet V, Levesque J, Bergeron A, Lacombe L, Dujardin T, Tiguert R, Fradet Y. S84 URANARY PCA3 AND CANCER PROGRESSION UNDER ACTIVE SURVILLANCE OF PROSTATE CANCER European Urology Supplements. 11: 154. DOI: 10.1016/S1569-9056(13)60277-8  0.478
2011 Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. The Journal of Urology. 186: 2228-32. PMID 22014796 DOI: 10.1016/j.juro.2011.07.119  0.417
2011 Mauermann J, Pouliot F, Fradet V. Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers. World Review of Nutrition and Dietetics. 102: 156-71. PMID 21865830 DOI: 10.1159/000327805  0.464
2011 Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E. SRD5A polymorphisms and biochemical failure after radical prostatectomy. European Urology. 60: 1226-34. PMID 21715084 DOI: 10.1016/J.Eururo.2011.06.020  0.322
2011 Fradet V, Lévesque J, Bergeron A, Lacombe L, Dujardin T, Tiguert R, Fradet Y. UP-02.184 Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer Urology. 78: S324. DOI: 10.1016/S1569-9056(13)60277-8  0.565
2011 Fradet V, Neveu B, Moreel X, Bergeron A, Larue H, Fradet Y. UP-02.084 Active Inflammatory State and Reactivity of Normal Prostate Epithelium and Aggressive Prostate Cancer Urology. 78: S288-S289. DOI: 10.1016/J.Urology.2011.07.902  0.549
2011 Fradet V, Lodde M, Mauermann J, Caron A, Lacombe L, Dujardin T, Fradet Y. POD-07.07 Long-Term Cancer Outcomes After Radical Prostatectomy and Selective Salvage Radiotherapy in 1670 Pt2-3N0M0 Patients by Margins Status: Quantification of Overtreatment with Adjuvant Radiotherapy for all Positive Margins Urology. 78: S25. DOI: 10.1016/J.Urology.2011.07.457  0.373
2011 Fradet V, Neveu B, Morel X, Julien P, Bergeron A, Larue H, Fradet Y. UP-02.229 Anti-Inflammatory Effects of Fish Oil (Omega-3 Fatty Acids) on Normal Human Prostate Epithelium Urology. 78: S340-S341. DOI: 10.1016/J.Urology.2011.07.1047  0.378
2010 Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 256: 176-83. PMID 20505068 DOI: 10.1148/Radiol.10091147  0.322
2010 Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2499-504. PMID 20406931 DOI: 10.1200/JCO.2009.26.9597  0.346
2009 Reese AC, Fradet V, Witte JS. Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. Journal of Nutrigenetics and Nutrigenomics. 2: 149-58. PMID 19776642 DOI: 10.1159/000235565  0.42
2009 Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2559-66. PMID 19318492 DOI: 10.1158/1078-0432.Ccr-08-2503  0.367
2009 Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. The Journal of Urology. 181: 1628-33; discussion . PMID 19233388 DOI: 10.1016/j.juro.2008.11.107  0.439
2009 Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. THE RELATIONSHIP BETWEEN LOCAL UROLOGIST DENSITY AND PROSTATE, BLADDER, AND KIDNEY CANCER MORTALITY Journal of Urology. 181: 163-163. DOI: 10.1016/S0022-5347(09)60468-7  0.501
2009 Conti S, Dall'Era M, Fradet V, Cowan JE, Simko J, Carroll PR. PATHOLOGIC OUTCOMES IN MEN MEETING CRITERIA FOR ACTIVE SURVEILLANCE OF PROSTATE CANCER Journal of Urology. 181: 60-60. DOI: 10.1016/S0022-5347(09)60179-8  0.542
2009 Karl A, Rittler P, Buchner A, Fradet V, Walther S, Stief CG. RISK OF MALNUTRITION IN UROLOGICAL PATIENTS Journal of Urology. 181: 8-8. DOI: 10.1016/S0022-5347(09)60033-1  0.307
2008 Fradet V, Sheehy O, Saad F, LeLorier J. Statins and superficial bladder cancer evolution after diagnosis: A population-based study Journal of Clinical Oncology. 26: 22047-22047. DOI: 10.1200/Jco.2008.26.15_Suppl.22047  0.408
2008 Fradet V, Paciorek A, Knight SJ, Carroll PR, Chan JM. INTAKE OF A HEALTHY DIET PATTERN AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH PROSTATE CANCER Journal of Urology. 179: 608-609. DOI: 10.1016/S0022-5347(08)61782-6  0.466
2008 Fradet V, Cheng I, Casey G, Witte JS. DIETARY LONG-CHAIN OMEGA-3 FATTY ACIDS, COX2 GENE POLYMORPHISM, AND AGGRESSIVE PROSTATE CANCER Journal of Urology. 179: 149-149. DOI: 10.1016/S0022-5347(08)60427-9  0.478
2006 Chun K, Briganti A, Steuber T, Walz J, Lebeau T, Fradet V, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz P. THE 2002 AJCC PATHOLOGICAL T2 SUBSTAGES CONFER NO PROGNOSTIC INFORMATION ON THE RATE OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS WITH PATHOLOGICALLY ORGAN CONFINED DISEASE AT RADICAL PROSTATECTOMY European Urology Supplements. 5: 279. DOI: 10.1016/S1569-9056(06)61029-4  0.495
2005 Fradet V, McCormack M, Perrotte P, Karakiewicz P, Saad F. An epidural abscess following transrectal ultrasound-guided biopsies of the prostate. The Canadian Journal of Urology. 12: 2899-900. PMID 16401377  0.393
2004 Fradet V, Lessard L, Mes-Masson A, Begin LR, Perrotte P, Karakiewicz PI, Saad F. 1093: NFKB Expression Predicts Biochemical Recurrence in Patients with Positive Margin Prostate Cancer Journal of Urology. 171: 288-288. DOI: 10.1016/S0022-5347(18)38330-7  0.547
Low-probability matches (unlikely to be authored by this person)
2017 Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V. Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. Nutrition and Cancer. 1-9. PMID 29083243 DOI: 10.1080/01635581.2017.1367941  0.292
2004 Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8460-4. PMID 15623625 DOI: 10.1158/1078-0432.Ccr-04-0764  0.288
2021 Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V. Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition Espen. 47: 221-226. PMID 35063205 DOI: 10.1016/j.clnesp.2021.12.011  0.284
2009 Odisho AY, Berry AB, Ahmad AE, Fradet V, Carroll PR, Konety BR. REFLEX IMMUNOCYT TESTING FOR DIAGNOSIS OF BLADDER CANCER IN PATIENTS WITH ATYPICAL URINE CYTOLOGY Journal of Urology. 181: 419-419. DOI: 10.1016/S0022-5347(09)61189-7  0.284
2015 Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C. Phase II drug metabolizing polymorphisms and smoking status predict recurrence of non-muscle invasive bladder cancer: a gene-smoking interaction. Cancer Prevention Research (Philadelphia, Pa.). PMID 26645279 DOI: 10.1158/1940-6207.Capr-15-0069  0.282
2020 Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V. Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 164: 102215. PMID 33276284 DOI: 10.1016/j.plefa.2020.102215  0.278
2014 Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urologic Oncology. 32: 839-45. PMID 24856978 DOI: 10.1016/J.Urolonc.2014.04.006  0.272
2017 Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V. Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29106362 DOI: 10.5489/Cuaj.4471  0.269
2012 Mauermann J, Fradet V, Hovington H, Lacombe L, Dujardin T, Tiguert R, Fradet Y. 786 Impact of extent of positive margins on different outcome parameters in 1712 treatment-naïve patients after pT2-4 N0 radical prostatectomy European Urology Supplements. 11: e786-e786a. DOI: 10.1016/S1569-9056(12)60783-0  0.269
2023 Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y. High infiltration of CD209 dendritic cells and CD163 macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes. Frontiers in Immunology. 14: 1205266. PMID 37435060 DOI: 10.3389/fimmu.2023.1205266  0.265
2015 Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 15: 2. PMID 25889163 DOI: 10.1186/S40644-015-0038-0  0.259
2023 Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Savard J, Diorio C, ... Fradet V, et al. Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA). Nutrients. 15. PMID 36986098 DOI: 10.3390/nu15061369  0.258
2007 Fradet V, Gaudreau C, Perrotte P, Côté J, Paquin JM. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 1: 269-72. PMID 18542802  0.251
2013 Alesawi A, Caron A, Bergeron A, Hovington H, Fradet V, Lacombe L, Fradet Y. 1297 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR PREOPERATIVE STAGING AND POSTOPERATIVE FOLLOW-UP OF UROTHELIAL CARCINOMA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2651  0.247
2021 Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 33750523 DOI: 10.5489/cuaj.7107  0.24
2017 Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V. Supplementary data: Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review Canadian Urological Association Journal. 11: E465-8. DOI: 10.5489/Cuaj.5102  0.24
2016 Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F. Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association For Cardio-Thoracic Surgery. PMID 27016196 DOI: 10.1093/Ejcts/Ezw023  0.238
2019 Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30110-1  0.215
2013 Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu B, Fradet V, Fradet Y. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Human Pathology. 44: 1630-7. PMID 23574787 DOI: 10.1016/J.Humpath.2013.01.014  0.206
2015 Alesawi AM, Levesque J, Fradet V. Malignant mesothelioma of the tunica vaginalis testis: comprehensive review of literature and case report Journal of Clinical Urology. 8: 147-152. DOI: 10.1177/2051415813511082  0.206
2007 Fradet V, Gaudreau C, Perrotte P, Côté J, Paquin JM. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer Journal of the Canadian Urological Association. 1: 269-272.  0.194
2017 Thériault B, Marceau-Grimard M, Blais AS, Fradet V, Moore K, Cloutier J. Urology residents on call: Investigating the workload and relevance of calls. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29381457 DOI: 10.5489/Cuaj.4333  0.19
2009 Witte JS, Simopoulos AP, Olivieri O, Hodis HN, Koletzko B, Lattka E, Illig T, Heinrich J, Allayee H, Roth N, Reese AC, Fradet V, Martinelli N, Consoli L. The European Nutrigenomics Organisation Journal of Nutrigenetics and Nutrigenomics. 2: 162-162. DOI: 10.1159/000249157  0.181
2023 Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M. Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 37931285 DOI: 10.5489/cuaj.8341  0.181
2021 Cléophat JE, Dorval M, El Haffaf Z, Chiquette J, Collins S, Malo B, Fradet V, Joly Y, Nabi H. Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings. Bmc Medical Genomics. 14: 167. PMID 34174888 DOI: 10.1186/s12920-021-01016-8  0.179
2009 Witte JS, Simopoulos AP, Olivieri O, Hodis HN, Koletzko B, Lattka E, Illig T, Heinrich J, Allayee H, Roth N, Reese AC, Fradet V, Martinelli N, Consoli L. Author and Subject Index Journal of Nutrigenetics and Nutrigenomics. 2: 159-159. DOI: 10.1159/000249154  0.178
2020 Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC. Building a Canadian Translational Bladder Cancer Research Network. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: E475-E481. PMID 33275556 DOI: 10.5489/cuaj.6887  0.174
2006 Chun FK, Briganti A, Lebeau T, Fradet V, Steuber T, Walz J, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz PI. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. European Urology. 49: 273-8; discussion 27. PMID 16413103 DOI: 10.1016/j.eururo.2005.12.009  0.172
2009 Fradet V, Allareddy V, Aaronson DS, Konety BR. Is the complication rate of radical cystectomy predictive of the complication rate of other urological procedures? The Journal of Urology. 181: 1054-9; discussion 1. PMID 19150541 DOI: 10.1016/j.juro.2008.11.016  0.146
2009 Karl A, Rittler P, Buchner A, Fradet V, Speer R, Walther S, Stief GC. Prospective assessment of malnutrition in urologic patients. Urology. 73: 1072-6. PMID 19232689 DOI: 10.1016/j.urology.2008.12.037  0.143
2022 Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P. Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. Urologic Oncology. PMID 36272848 DOI: 10.1016/j.urolonc.2022.09.024  0.138
2008 Fradet V, Konety BR. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. Bju International. 101: 257-8; author reply . PMID 18173826 DOI: 10.1111/j.1464-410X.2007.07394_2.x  0.106
2009 Smith JF, Brant WO, Fradet V, Shindel AW, Vittinghoff E, Chi T, Huang YC, Davis CB, Conti S, Lue TF. Penile sonographic and clinical characteristics in men with Peyronie's disease. The Journal of Sexual Medicine. 6: 2858-67. PMID 19732312 DOI: 10.1111/J.1743-6109.2009.01438.X  0.102
2008 Fradet V, Konety BR. Re: results from three municipal hospitals regarding radical cystectomy on elderly patients. International Braz J Urol : Official Journal of the Brazilian Society of Urology. 34: 97-8. PMID 18341727  0.091
2014 Rhéaume-Lanoie J, Lepanto L, Fradet V, Billiard JS, Tang A. Diagnostic performance of ultrasound for macroscopic hematuria in the era of multidetector computed tomography urography. Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes. 65: 253-9. PMID 24316140 DOI: 10.1016/j.carj.2013.08.001  0.082
2014 Hubault M, Sourty C, Jacquin-Courtois S, Luaute J, Lalau D, Fradet V, Rode G, Janoly-Dumenil A. Anti-vitamine K et alimentation : que sait-on ? Que dit-on au patient ? Résultats d’une enquête auprès des professionnels de santé Le Pharmacien Hospitalier Et Clinicien. 49: e172-e173. DOI: 10.1016/J.PHCLIN.2014.04.342  0.041
2009 Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. Geographic distribution of urologists throughout the United States using a county level approach. The Journal of Urology. 181: 760-5; discussion 76. PMID 19091334 DOI: 10.1016/j.juro.2008.10.034  0.04
2004 Cardinal H, Barama AA, Fradet V, Lallier M, Lévesque R, St Louis G, Hébert MJ, Girardin C, Pâquet M, Daloze P. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression. Transplantation Proceedings. 36: 448S-450S. PMID 15041384 DOI: 10.1016/j.transproceed.2004.01.053  0.025
Hide low-probability matches.